Citadel Reports 9.6% Stake in Lexeo Therapeutics (LXEO)

Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO).

Rhea-AI Filing Summary

Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO). Collectively, Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC report beneficial ownership of 5,325,269 shares, representing 9.6% of outstanding shares on a fully calculated basis of 55,718,516 shares (including 1,717,302 shares issuable upon warrant conversion). Citadel Securities entities separately report 8,843 shares. Kenneth Griffin is reported to beneficially own 5,334,112 shares (also 9.6%). The filing states the positions were not acquired to change or influence control and identifies the reporting persons, organization structure and shared voting/dispositive powers.

Positive

• Material ownership disclosed: Citadel-affiliated entities report a clear 9.6% beneficial stake in LXEO, improving market transparency
• Detailed ownership structure: Filing identifies specific entities, shared voting and dispositive powers, and inclusion of shares issuable upon warrant conversion
• Passive intent certified: Reporting persons certify the holdings were not acquired to change or influence control, consistent with Schedule 13G treatment

Negative

• None.

Insights

Financial Analyst

TL;DR: Citadel affiliates disclosed a sizable 9.6% passive stake in LXEO, a material ownership position that increases institutional concentration.

The Schedule 13G shows a nearly 10% position held collectively by Citadel-managed funds and related entities, using a 55.7 million share base that includes convertible warrants. For investors this raises institutional concentration and potential liquidity considerations; the filing characterizes the stake as passive under Section 13(g), which implies no intent to influence control. The precise share counts and shared voting/dispositive powers are disclosed, improving transparency around ownership structure.

Corporate Governance Expert

TL;DR: A 9.6% disclosure is material for governance monitoring but the filer affirms passive intent under Schedule 13G.

The document identifies the reporting chain (portfolio manager, holding companies, GP entities, and Kenneth Griffin) and quantifies shared voting and dispositive power, which is important for directors and governance committees tracking influential holders. The explicit certification that shares were not acquired to change control reduces immediate takeover or activist signaling, though the position size warrants ongoing disclosure monitoring.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXEO shares do Citadel entities report owning?

The filing reports Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC beneficially own 5,325,269 shares; Citadel Securities reports 8,843 shares.

What percentage of LXEO does the reported position represent?

The reported position represents 9.6% of LXEO's outstanding shares based on 55,718,516 shares used in the filing's calculation.

Does the filing indicate intent to influence control of Lexeo Therapeutics (LXEO)?

No. The certification states the securities were not acquired and are not held to change or influence control, consistent with a Schedule 13G passive filing.

Who among the Citadel reporting persons is individually identified as a beneficial owner?

Mr. Kenneth Griffin is identified and may be deemed to beneficially own 5,334,112 shares.

Does the ownership count include potential shares from warrant conversion?

Yes. The 55,718,516-share base includes 1,717,302 shares issuable upon conversion of certain warrants held by affiliates, per the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:58 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Lexeo Therapeutics, Inc.

(Name of Issuer)

Common Stock ($0.0001 par value) (the "Shares")

(Title of Class of Securities)

52886X107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,325,269.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,325,269.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,325,269.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.6 %

12

Type of Reporting Person (See Instructions)

IA, HC, OO

Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 55,718,516 Shares outstanding comprised of (i) 54,001,214 Shares outstanding as of June 2, 2025 (according to the issuer's registration statement on From S-3 as filed with the Securities and Exchange Commission on June 13, 2025), and (ii) 1,717,302 Shares issuable upon conversion of certain warrants held by affiliates of the reporting persons.

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel Advisors Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,325,269.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,325,269.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,325,269.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.6 %

12

Type of Reporting Person (See Instructions)

HC, PN

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,325,269.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,325,269.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,325,269.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.6 %

12

Type of Reporting Person (See Instructions)

HC, OO

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel Securities LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,843.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,843.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,843.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

BD, OO

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel Securities Group LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,843.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,843.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,843.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, PN

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Citadel Securities GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,843.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,843.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,843.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, OO

SCHEDULE 13G

CUSIP No. 52886X107

1

Names of Reporting Persons

Kenneth Griffin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,334,112.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,334,112.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,334,112.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.6 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lexeo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 345 Park Avenue South, Floor 6, New York, NY, 10010
Item 2.
(a)	Name of person filing: This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), Citadel CEMF Investments Ltd., a Cayman Islands limited company ("CCIL"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM and CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
(b)	Address or principal business office or, if none, residence: The address of each of the Reporting Persons is 830 Brickell Plaza, Miami, Florida 33131.
(c)	Citizenship: Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
(d)	Title of class of securities: Common Stock ($0.0001 par value) (the "Shares")
(e)	CUSIP No.: 52886X107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 5,325,269 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 8,843 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 8,843 Shares. 4. Mr. Griffin may be deemed to beneficially own 5,334,112 Shares.
(b)	Percent of class: 1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 9.6% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 9.6% of the Shares outstanding.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0
	(ii) Shared power to vote or to direct the vote: 1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 5,325,269 2. Citadel Securities LLC: 8,843 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 8,843 4. Mr. Griffin: 5,334,112
	(iii) Sole power to dispose or to direct the disposition of: 1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0
	(iv) Shared power to dispose or to direct the disposition of: 1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 5,325,269 2. Citadel Securities LLC: 8,843 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 8,843 4. Mr. Griffin: 5,334,112
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Citadel Advisors LLC

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Citadel Advisors Holdings LP

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Citadel GP LLC

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Citadel Securities LLC

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Citadel Securities Group LP

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Citadel Securities GP LLC

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, Authorized Signatory
Date:	08/14/2025

Kenneth Griffin

Signature:	/s/ Seth Levy
Name/Title:	Seth Levy, attorney-in-fact*
Date:	08/14/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.